Effect of ARID1A mutation and expression on prognosis of hepatocellular carcinoma and cholangiocarcinoma: a meta-analysis
Abstract Background: Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the most common liver malignant tumors worldwide. Investigating the molecular basis of these malignancies is vital to the development of new treatments. Recent studies have found that mutation and abnormal expression of ARID1A, are frequently shown in HCC and cholangiocarcinoma. Herein, we aimed to estimate the effects of ARID1A mutation and expression on prognosis of HCC and cholangiocarcinoma.Methods: We searched PubMed, EMBASE, Web of Science, the Cochrane Library for studies evaluating the relationship between ARID1A mutations or expression and the survival of HCC or cholangiocarcinoma patients. Meta-analysis was performed to generate a combined HR with a 95% confidence interval (CI) for overall survival (OS).Results: We identified 12 articles that evaluated the impact of ARID1A mutation or expression on the prognosis of patients with HCC or cholangiocarcinoma. Six studies provided data on HCC survival and 6 studies examined cholangiocarcinoma survival. For HCC, ARID1A mutation carriers or patients with low ARID1A expression had worse OS (HR = 1.75; 95% CI = 1.22–2.51) than non-carriers or patients with high ARID1A expression. For cholangiocarcinoma, ARID1A mutation carriers or patients with low ARID1A expression also had significantly shorter OS (HR = 3.70, 95% CI = 2.88–4.76).Conclusions: Our study suggests that ARIDIA mutation or low expression is strongly associated with poor prognosis of patients with HCC or cholangiocarcinoma, and may be considered as a potential prognostic biomarker for these patients.